Cartesian Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CARTESIAN THERAPEUTICS, INC. | ||
| Date: March 13, 2025 | By: | /s/ Carsten Brunn, Ph.D. |
|---|---|---|
| Carsten Brunn, Ph.D. | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Carsten Brunn, Ph.D. | President and Chief Executive Officer, and Director | March 13, 2025 |
| Carsten Brunn, Ph.D. | (Principal Executive Officer) | |
| /s/ Blaine Davis | Chief Financial Officer | March 13, 2025 |
| Blaine Davis | (Principal Financial and Accounting Officer) | |
| /s/ Carrie S. Cox | Director | March 13, 2025 |
| Carrie S. Cox | ||
| /s/ Timothy C. Barabe | Director | March 13, 2025 |
| Timothy C. Barabe | ||
| /s/ Nishan de Silva, M.D. | Director | March 13, 2025 |
| Nishan de Silva, M.D. | ||
| /s/ Murat Kalayoglu, M.D., Ph.D. | Director | March 13, 2025 |
| Murat Kalayoglu, M.D., Ph.D. | ||
| /s/ Kemal Malik MBBS | Director | March 13, 2025 |
| Kemal Malik, MBBS | ||
| /s/ Michael Singer, M.D., Ph.D. | Director | March 13, 2025 |
| Michael Singer, M.D., Ph.D. | ||
| /s/ Timothy Springer, Ph.D. | Director | March 13, 2025 |
| Timothy Springer, Ph.D. | ||
| /s/ Patrick Zenner | Director | March 13, 2025 |
| Patrick Zenner | ||
| Index to Consolidated Financial Statements | Pages |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-2 |
| Consolidated Balance Sheets at December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) for the years ended December 31, 2024 and 2023 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.